Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment (Advances in Experimental Medicine & Biology (Springer))

ISBN: 0306447207

Author: Ceriani, Roberto L.

Condition: New

Session I.- Breast Mucin and Associated Antigens in Diagnosis and Therapy.- Peptide Epitopes in Breast Cancer Mucins.- Does a Novel Form of the Breast Cancer Marker Protein, MUC1, Act as a Receptor Molecule that Modulates Signal Transduction?.- Cancer Metastasis Determined by Carbohydrate-Mediated Cell Adhesion.- Experimental Immunotherapy of Breast Cancer Using Alpha Interferon Conjugated to Monoclonal Antibody Mc5.- Circulating and Tissue Markers in the Longitudinal Management of Breast Cancer Patients.- Session II.- Engineering of Antibodies for Breast Cancer Therapy: Construction of Chimeric and Humanized Versions of the Murine Monoclonal Antibody BrE-3.- Humanization of an Anti-Mucin Antibody for Breast and Ovarian Cancer Therapy.- Towards an Immunotherapy for p185HER2 Overexpressing Tumors.- Session III.- Branching N-Linked Oligosaccharides in Breast Cancer.- Specificity of the IgG Response in Mice and Human Breast Cancer Patients Following Immunization Against Synthetic Sialyl-Tn, an Epitope with Possible Functional Significance in Metastasis.- Vaccination Against Breast Cancer - Studies in an Animal Model.- Anti-Idiotype Antibodies as Potential Therapeutic Agents for Human Breast Cancer.- The Simultaneous Expression of c-erbB-2 Oncoprotein and Laminin Receptor on Primary Breast Tumors has a Predicting Potential Analogous to that of the Lymph Node Status.- Multivariate Prognostic Model for Infiltrating Ductal Carcinoma of the Breast in the Axillary Node-Free Patient.- The Use of Monoclonal Antibody Immunoconjugates in Cancer Therapy.- Radioimmunolocalization of Breast Cancer Using BrE-3 Monoclonal Antibody.- Suppression of Human Anti-Mouse Antibody Response to Murine Monoclonal Antibody L6 by Deoxyspergualin: A Phase I Study.- Overview of Radioimmunotherapy in Advanced Breast Cancer Using 1-131 Chimeric L6.- Contributors.